~~<i id='EADE78455D'><strike id='EADE78455D'><tt id='EADE78455D'><pre id='EADE78455D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

explore

author：Wikipedia 2025-10-01 22:16:28 - browse：66

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： STAT Virtual Event: ASCO Recap, Live!

explore

hotspot

Wikipedia

knowledge

explore

leisure time

ErosDervishiforSTATBrittHermesonceconsideredherselfadoctor.Now,she’sanapostate.Hermesspentthreeyears

WSS

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

New report analyzes digital physical therapy solutions' effectiveness

Curing rare childhood diseases will falter unless Congress steps up

Poor hospice wound care hurts patients and families

Curing rare childhood diseases will falter unless Congress steps up

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

hotspot

explore

explore

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

State Dept. review finds Biden bears some blame for Afghanistan failures

Statins may not be needed by millions of people, study suggests

Activists slam private health insurers over coverage restrictions

Pharma companies must ensure equitable access to obesity drugs

Walensky prepares to leave CDC — and Congress — behind

In key trial, Verve's treatment lowers cholesterol levels in patients

Heart attack and stroke risk calculators need revising

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

hotspot

Readers discuss the intersection of pregnancy and addiction

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Gain of function research would be limited under House proposal

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Study: Why relieving medical debt did not improve financial outcomes

David Sabatini, ex

Wikipedia

knowledge

explore

leisure time